Abstract
Potential biomarkers that can assess the risk of coronary heart disease (CHD) and facilitate its preclinical detection are urgently needed. We aimed to explore the association between blood-based ACTB methylation and future CHD risk in a nested case-control study in the Chinese population. The methylation level of ACTB was quantitatively determined by mass spectrometry in 171 subclinical CHD cases and 356 controls. Logistic regression was used to examine the association between ACTB methylation and future CHD risk. We observed a significant association between hypermethylation of ACTB in peripheral blood and an increased risk of future CHD, particularly among individuals ≥ 60 years old and male subjects. Additionally, hypermethylation of ACTB was associated with the risk of future CHD in subjects with elevated TC and LDL-C levels. Furthermore, compared to using traditional risk factors alone, the model incorporating altered ACTB methylation demonstrated improved discriminative value, especially in individuals ≥ 60 years old and among males (area under curve = 0.79 and 0.81, respectively). Our findings demonstrated a strong association between ACTB hypermethylation in peripheral blood and increased future CHD risk, offering promise for improving risk assessment and early detection strategies.
Similar content being viewed by others
Acknowledgements
We would like to thank Jun Wang, Feifei Di, Zheng Zhang, Ling Wang, and Jin Zhang from Nanjing TANTICA Biotechnology Co. Ltd. for their contribution to the sample processing.
Funding
This work was supported by the National Natural Science Foundation of China (No. 82173611 and 81872686), the National Key Research and Development Program of China (No.2018YFC 2000703).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Jin, J., Wang, F., Li, M. et al. ACTB hypermethylation in blood is a potential biomarker as predictor to the risk of coronary heart disease. Sci Rep (2026). https://doi.org/10.1038/s41598-026-49875-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-49875-4
